title: The psychometric validation of a US English satisfaction measure for patients with benign prostatic hyperplasia and lower urinary tract symptoms.
abstract: BACKGROUND
  The purpose of the current study was to validate the US English Patient Perception of Study Medication (PPSM) questionnaire, which measures patient satisfaction with Benign Prostatic Hyperplasia (BPH) treatment and was administered to men with BPH lower urinary tract symptoms (LUTS) enrolled in a multi-national clinical trial.
  
  
  METHODS
  Patients with moderate to severe BPH symptoms completed three disease-specific measures: The International Prostate Symptom Score (IPSS), the BPH Impact Index (BII) and the PPSM, at baseline (after completion of the placebo run-in period) and at every 13-week clinic visit thereafter for the duration of the study treatment period. The PPSM was analysed to assess its variability, reliability and validity.
  
  
  RESULTS
  There were 879 patients included in the analyses, with a mean age of 66.7 years. The PPSM was found to comprise two factors - PPSM-Global and PPSM-Pain, with a Total Score ranging from 7 to 49. It demonstrated good internal consistency (Cronbach's alpha ranged from .95 to .97) and also demonstrated convergent validity through significant correlations with the IPSS (.48 to .58), IPSS Quality of Life (QoL) item (.41 to .63) and BII (.31 to .45) and known-groups validity against the IPSS, IPSS QoL item and BII.
  
  
  CONCLUSIONS
  Results support the use of the PPSM as a measure of satisfaction in BPH patient groups.
authors: GlaxoSmithKline, Research Triangle Park, NC, USA. libby.k.black@gsk.com
authors: Libby
authors: L
authors: Black
authors: Alyson
authors: A
authors: Grove
authors: Betsy
authors: B
authors: Morrill
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D004359:Drug Therapy, Combination; D006801:Humans; D007802:Language; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction / Q000706:statistics & numerical data*; D011470:Prostatic Hyperplasia / Q000145:classification / Q000188:drug therapy* / Q000523:psychology*; D011594:Psychometrics / Q000592:standards*; D011788:Quality of Life; D015203:Reproducibility of Results; D012720:Severity of Illness Index; D014481:United States; D016055:Urinary Retention / Q000188:drug therapy / Q000209:etiology / Q000523:psychology*